Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance

Journal of Experimental Medicine

Volumn 212, Issue 13, 2015, Pages 2223-2234

  Vukovic, Milica ^a   Guitart, Amelie V ^a   Sepulveda, Catarina ^a   Villacreces, Arnaud ^a   O'Duibhir, Eoghan ^a   Panagopoulou, Theano I ^a   Ivens, Alasdair ^b   Menendez Gonzalez, Juan ^a   Iglesias, Juan Manuel ^c   Allen, Lewis ^a   Glykofrydis, Fokion ^a   Subramani, Chithra ^a   Armesilla Diaz, Alejandro ^a   Post, Annemarie E M ^a   Schaak, Katrin ^a   Gezer, Deniz ^a,d,e   So, Chi Wai Eric ^f   Holyoake, Tessa L ^e   Wood, Andrew ^b   O'Carroll, Dónal ^a,g   Ratcliffe, Peter J ^h   Kranc, Kamil R ^a,b   more..

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Synpromics Ltd   (United Kingdom)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; STEM CELL FACTOR; TRANSCRIPTION FACTOR HOXA9; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HOMEODOMAIN PROTEIN; MYELOID ECOTROPIC VIRAL INTEGRATION SITE 1 PROTEIN; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; CRISPR CAS SYSTEM; FATTY ACID OXIDATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE SILENCING; GENOTYPE; GLYCOLYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIC STEM CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ACUTE MYELOID LEUKEMIA; ANIMAL; CELL HYPOXIA; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CRISPR-CAS SYSTEMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HOMEODOMAIN PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS;

EID: 84961215836     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20150452     Document Type: Article

References (40)

1. Andersson, A.K., J. Ma, J. Wang, X. Chen, A.L. Gedman, J. Dang, J. Nakitandwe, L. Holmfeldt, M. Parker, J. Easton, et al. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project. 2015. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 47:330-337. http://dx.doi.org/10.1038/ng.3230
2. Bernot, K.M., J.S. Nemer, R. Santhanam, S. Liu, N.A. Zorko, S.P. Whitman, K.E. Dickerson, M. Zhang, X. Yang, K.K. McConnell, et al. 2013. Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Blood. 122:3778-3783. http://dx.doi.org/10.1182/blood-2013-06-507426
3. Cancer Genome Atlas Research Network. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368:2059-2074. http://dx.doi.org/10.1056/NEJMoa1301689
4. Chang, E., H. Liu, K. Unterschemmann, P. Ellinghaus, S. Liu, V. Gekeler, Z. Cheng, D. Berndorff, and S.S. Gambhir. 2015. 18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243. Clin. Cancer Res. 21:335-346. http://dx.doi.org/10.1158/1078-0432.CCR-14-0217
5. Chen, W., A.R. Kumar, W.A. Hudson, Q. Li, B. Wu, R.A. Staggs, E.A. Lund, T.N. Sam, and J.H. Kersey. 2008. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell. 13:432-440. http://dx.doi.org/10.1016/j.ccr.2008.03.005
6. Dobson, C.L., A.J. Warren, R. Pannell, A. Forster, I. Lavenir, J. Corral, A.J. Smith, and T.H. Rabbitts. 1999. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J. 18:3564-3574. http://dx.doi.org/10.1093/emboj/18.13.3564
7. Drabkin, H.A., C. Parsy, K. Ferguson, F. Guilhot, L. Lacotte, L. Roy, C. Zeng, A. Baron, S.P. Hunger, M. Varella-Garcia, et al. 2002. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia. 16:186-195. http://dx.doi.org/10.1038/sj.leu.2402354
8. Ellinghaus, P., I. Heisler, K. Unterschemmann, M. Haerter, H. Beck, S. Greschat, A. Ehrmann, H. Summer, I. Flamme, F. Oehme, et al. 2013. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2:611-624. http://dx.doi.org/10.1002/cam4.112
9. Gezer, D., M. Vukovic, T. Soga, P.J. Pollard, and K.R. Kranc. 2014. Concise review: genetic dissection of hypoxia signaling pathways in normal and leukemic stem cells. Stem Cells. 32:1390-1397. http://dx.doi.org/10.1002/stem.1657
10. Guitart, A.V., C. Subramani, A. Armesilla-Diaz, G. Smith, C. Sepulveda, D. Gezer, M. Vukovic, K. Dunn, P. Pollard, T.L. Holyoake, et al. 2013. Hif-2α is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood. 122:1741-1745. http://dx.doi.org/10.1182/blood-2013-02-484923
11. Helbig, L., L. Koi, K. Brüchner, K. Gurtner, H. Hess-Stumpp, K. Unterschemmann, M. Baumann, D. Zips, and A. Yaromina. 2014. BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a scheduledependent manner in head and neck human xenografts. Radiat. Oncol. 9:207. http://dx.doi.org/10.1186/1748-717X-9-207
12. Hu, Y., and G.K. Smyth. 2009. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods. 347:70-78. http://dx.doi.org/10.1016/j.jim.2009.06.008
13. Kranc, K.R., H. Schepers, N.P. Rodrigues, S. Bamforth, E. Villadsen, H. Ferry, T. Bouriez-Jones, M. Sigvardsson, S. Bhattacharya, S.E. Jacobsen, and T. Enver. 2009. Cited2 is an essential regulator of adult hematopoietic stem cells. Cell Stem Cell. 5:659-665. http://dx.doi.org/10.1016/j.stem.2009.11.001
14. Kroon, E., J. Krosl, U. Thorsteinsdottir, S. Baban, A.M. Buchberg, and G. Sauvageau. 1998. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 17:3714-3725. http://dx.doi.org/10.1093/emboj/17.13.3714
15. Kumar, A.R., Q. Li, W.A. Hudson, W. Chen, T. Sam, Q. Yao, E.A. Lund, B. Wu, B.J. Kowal, and J.H. Kersey. 2009. A role for MEIS1 in MLL-fusion gene leukemia. Blood. 113:1756-1758. http://dx.doi.org/10.1182/blood-2008-06-163287
16. Kumatori, A., K. Tanaka, N. Inamura, S. Sone, T. Ogura, T. Matsumoto, T. Tachikawa, S. Shin, and A. Ichihara. 1990. Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. USA. 87:7071-7075. http://dx.doi.org/10.1073/pnas.87.18.7071
17. Kwon, H.Y., J. Bajaj, T. Ito, A. Blevins, T. Konuma, J. Weeks, N.K. Lytle, C.S. Koechlein, D. Rizzieri, C. Chuah, et al. 2015. Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. Cell Stem Cell. 17:152-164. http://dx.doi.org/10.1016/j.stem.2015.06.006
18. Lavallée, V.P., I. Baccelli, J. Krosl, B. Wilhelm, F. Barabé, P. Gendron, G. Boucher, S. Lemieux, A. Marinier, S. Meloche, et al. 2015. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat. Genet. 47:1030-1037. http://dx.doi.org/10.1038/ng.3371
19. Lawrence, H.J., S. Rozenfeld, C. Cruz, K. Matsukuma, A. Kwong, L. Kömüves, A.M. Buchberg, and C. Largman. 1999. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia. 13:1993-1999. http://dx.doi.org/10.1038/sj.leu.2401578
20. Lehnertz, B., C. Pabst, L. Su, M. Miller, F. Liu, L. Yi, R. Zhang, J. Krosl, E. Yung, J. Kirschner, et al. 2014. The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 28:317-327. http://dx.doi.org/10.1101/gad.236794.113
21. Lessard, J., and G. Sauvageau. 2003. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 423:255-260. http://dx.doi.org/10.1038/nature01572
22. Ley, T.J., E.R. Mardis, L. Ding, B. Fulton, M.D. McLellan, K. Chen, D. Dooling, B.H. Dunford-Shore, S. McGrath, M. Hickenbotham, et al. 2008. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 456:66-72. http://dx.doi.org/10.1038/nature07485
23. Losman, J.A., and W.G. Kaelin Jr. 2013. What a difference a hydroxyl makes:mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27:836-852. http://dx.doi.org/10.1101/gad.217406.113
24. Ma, W., H. Kantarjian, B. Bekele, A.C. Donahue, X. Zhang, Z.J. Zhang, S. O'Brien, E. Estey, Z. Estrov, J. Cortes, et al. 2009. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin. Cancer Res. 15:3820-3826. http://dx.doi.org/10.1158/1078-0432.CCR-08-3034
25. Mole, D.R., C. Blancher, R.R. Copley, P.J. Pollard, J.M. Gleadle, J. Ragoussis, and P.J. Ratcliffe. 2009. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 284:16767-16775. http://dx.doi.org/10.1074/jbc.M901790200
26. Murai, M., M. Toyota, A. Satoh, H. Suzuki, K. Akino, H. Mita, Y. Sasaki, T. Ishida, L. Shen, G. Garcia-Manero, et al. 2005. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br. J. Cancer. 92:1165-1172. http://dx.doi.org/10.1038/sj.bjc.6602422
27. Rouault-Pierre, K., L. Lopez-Onieva, K. Foster, F. Anjos-Afonso, I. Lamrissi-Garcia, M. Serrano-Sanchez, R. Mitter, Z. Ivanovic, H. de Verneuil, J. Gribben, et al. 2013. HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell. 13:549-563. http://dx.doi.org/10.1016/j.stem.2013.08.011
28. Sanjana, N.E., O. Shalem, and F. Zhang. 2014. Improved vectors and genomewide libraries for CRI SPR screening. Nat. Methods. 11:783-784. http://dx.doi.org/10.1038/nmeth.3047
29. Schödel, J., S. Oikonomopoulos, J. Ragoussis, C.W. Pugh, P.J. Ratcliffe, and D.R. Mole. 2011. High-resolution genome-wide mapping of HIFbinding sites by ChIP-seq. Blood. 117:e207-e217. http://dx.doi.org/10.1182/blood-2010-10-314427
30. Semenza, G.L. 2014. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9:47-71. http://dx.doi.org/10.1146/annurev-pathol-012513-104720
31. Servida, F., D. Soligo, D. Delia, C. Henderson, C. Brancolini, L. Lombardi, and G.L. Deliliers. 2005. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia. 19:2324-2331. http://dx.doi.org/10.1038/sj.leu.2403987
32. Somervaille, T.C., C.J. Matheny, G.J. Spencer, M. Iwasaki, J.L. Rinn, D.M. Witten, H.Y. Chang, S.A. Shurtleff, J.R. Downing, and M.L. Cleary. 2009. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell. 4:129-140. http://dx.doi.org/10.1016/j.stem.2008.11.015
33. Sowter, H.M., P.J. Ratcliffe, P. Watson, A.H. Greenberg, and A.L. Harris. 2001. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61:6669-6673.
34. Spencer, J.A., F. Ferraro, E. Roussakis, A. Klein, J. Wu, J.M. Runnels, W. Zaher, L.J. Mortensen, C. Alt, R. Turcotte, et al. 2014. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. 508:269-273. http://dx.doi.org/10.1038/nature13034
35. van der Helm, L.H., M.C. Bosman, J.J. Schuringa, and E. Vellenga. 2015. Effective targeting of primitive AML CD34(+) cells by the secondgeneration proteasome inhibitor carfilzomib. Br. J. Haematol. 171:652-655. http://dx.doi.org/10.1111/bjh.13418
36. Velasco-Hernandez, T., A. Hyrenius-Wittsten, M. Rehn, D. Bryder, and J. Cammenga. 2014. HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia. Blood. 124:3597-3607. http://dx.doi.org/10.1182/blood-2014-04-567065
37. Vyas, P. 2014. Targeting HIF function: the debate continues. Blood. 124:3510-3511. http://dx.doi.org/10.1182/blood-2014-10-605055
38. Wang, Y., A.V. Krivtsov, A.U. Sinha, T.E. North, W. Goessling, Z. Feng, L.I. Zon, and S.A. Armstrong. 2010. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 327:1650-1653. http://dx.doi.org/10.1126/science.1186624
39. Wang, Y., Y. Liu, S.N. Malek, P. Zheng, and Y. Liu. 2011. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 8:399-411. http://dx.doi.org/10.1016/j.stem.2011.02.006
40. Wong, S.H., D.L. Goode, M. Iwasaki, M.C. Wei, H.P. Kuo, L. Zhu, D. Schneidawind, J. Duque-Afonso, Z. Weng, and M.L. Cleary. 2015. The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential. Cancer Cell. 28:198-209. http://dx.doi.org/10.1016/j.ccell.2015.06.003